Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer
NCT ID: NCT02599714
Last Updated: 2024-06-06
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
54 participants
Study Classification
INTERVENTIONAL
Study Start Date
2015-12-07
Study Completion Date
2023-11-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This dose finding/extension study was designed originally to consist of three parts: Part A was intended to identify the MTD of the AZD2014/ palbociclib combination on a background of fulvestrant (referred to as the triplet) in postmenopausal women with locally advanced/ metastatic estrogen receptor positive (ER+) breast cancer. Part B was to further characterize safety, tolerability, PK, and preliminary efficacy in single-arm dose expansion groups. Part C was to be a Phase 2, randomized, double-blind, extension comparing the triplet and doublet combinations. Part C was deleted from the protocol and was not performed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT03709082
HER2-positive Breast Cancer
Breast Cancer Metastatic
TERMINATED
PHASE1/PHASE2
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
NCT00570258
Metastatic Breast Cancer
TERMINATED
PHASE2
ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)
NCT04669587
Estrogen Receptor-Positive
HER2-Negative
Locally Advanced Breast Cancer
+1 more
UNKNOWN
PHASE1/PHASE2
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
NCT06188520
ER+ HER2- Advanced Breast Cancer
High-grade Serous Ovarian Cancer (HGSOC)
RECRUITING
PHASE1/PHASE2
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
NCT01349959
Male Breast Carcinoma
Recurrent Breast Carcinoma
Stage IIIC Breast Cancer AJCC v7
+2 more
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This dose finding/extension study was designed originally to consist of three parts:
Part A is a Phase 1 triplet-dose finding investigation in 3-6 patients per cohort to determine the maximum tolerated dose (MTD) of the triplet.
Part B is a single arm expansion in approximately 27 patients evaluable for response to define the recommended Phase 2 dose (RP2D).
Part C was intended to investigate the efficacy of the triplet combination at the RP2D in a randomized, double-blind, placebo-controlled, stratified, parallel group extension. Part C was intended to include ER+, locally advanced and/or metastatic breast cancer patients who have progressed following prior non-steroidal aromatase inhibitor (NSAI) endocrine therapy. Patients in Part C were to be randomized to receive either the triplet combination (AZD2014 + palbociclib + fulvestrant) or the doublet (matching AZD2014 placebo + palbociclib + fulvestrant). Patients were to be stratified according to hormone sensitivity, presence of visceral metastases, and prior CDK inhibitor treatment. Part C would have been conducted if indicated by the emerging data.
Part A is a Phase 1 triplet-dose finding investigation in 3-6 patients per cohort to determine the maximum tolerated dose (MTD) of the triplet.
Part B is a single arm expansion in approximately 27 patients evaluable for response to define the recommended Phase 2 dose (RP2D).
Part C was intended to investigate the efficacy of the triplet combination at the RP2D in a randomized, double-blind, placebo-controlled, stratified, parallel group extension. Part C was intended to include ER+, locally advanced and/or metastatic breast cancer patients who have progressed following prior non-steroidal aromatase inhibitor (NSAI) endocrine therapy. Patients in Part C were to be randomized to receive either the triplet combination (AZD2014 + palbociclib + fulvestrant) or the doublet (matching AZD2014 placebo + palbociclib + fulvestrant). Patients were to be stratified according to hormone sensitivity, presence of visceral metastases, and prior CDK inhibitor treatment. Part C would have been conducted if indicated by the emerging data.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Advanced and Metastatic Breast Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study was originally designed as randomized and double blinded. Currently (CSP v.8.0 of 14-Dec-2021) no masking and no randomization is planned.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Triplet Combination (Dose Finding)
Phase 1 triplet dose finding phase in 3-6 patients per cohort - approximately 30 patients depending on emerging data to determine the maximum tolerated dose (MTD) of the triplet.
Group Type
EXPERIMENTAL
AZD2014
Intervention Type
DRUG
The triplet combination will be comprised of AZD2014 + palbociclib + fulvestrant.
Palbociclib
Intervention Type
DRUG
cyclin dependent kinase inhibitor
Fulvestrant
Intervention Type
DRUG
Fulvestrant hormonal therapy as background
Triplet Combination (Dose Expansion)
Additional patients will be enrolled at the dose determined in Part A.
Group Type
EXPERIMENTAL
AZD2014
Intervention Type
DRUG
The triplet combination will be comprised of AZD2014 + palbociclib + fulvestrant.
Palbociclib
Intervention Type
DRUG
cyclin dependent kinase inhibitor
Fulvestrant
Intervention Type
DRUG
Fulvestrant hormonal therapy as background
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD2014
The triplet combination will be comprised of AZD2014 + palbociclib + fulvestrant.
Intervention Type
DRUG
Palbociclib
cyclin dependent kinase inhibitor
Intervention Type
DRUG
Fulvestrant
Fulvestrant hormonal therapy as background
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
vistusertib
Ibrance
PD-0332991
Faslodex
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Signed and dated written informed consent prior to any mandatory study specific procedures, sampling and analyses.
2. Signed and dated written informed consent for tumour biopsies. If the tumour is found not to be safely accessible the biopsy will not be taken. Accessible lesions are defined as those which are biopsiable and amenable to repeat biopsy, unless clinically contraindicated. In this case the patient will remain in the study and there will be no penalty or loss of benefit to the patient and they will not be excluded from other aspects of the study.
3. Postmenopausal women aged ≥ 18 years
4. Negative pregnancy test prior to dosing and willing to use a highly effective method of contraception for the duration of the study and for 90 days after the last dose of IP if they are under 50 unless they have medically confirmed irreversible premature ovarian failure, bilateral oophorectomy, bilateral salpinectomy, or complete or partial hysterectomy.
Highly effective methods of contraception are:
• Use of oral, injected or implanted hormonal methods of contraception which inhibit ovulation, either estrogen and progestogen containing intravaginal, transdermal) or only progesterone containing (oral, injectable, implantable)
• Placement of an intrauterine device (IUD or intrauterine system (IUS)
• True abstinence
* Bilateral tubal ligation
* Vasectomised partner
5. World Health Organisation/Eastern Cooperative Oncology Group (ECOG) performance status of patient is 0-1 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks.
6. Histologically or cytologically proven diagnosis of breast cancer with evidence of locally advanced or metastatic disease, not amenable to resection or radiation therapy with curative intent.
7. Documentation of estrogen receptor positive (ER+) breast cancer based on most recent tumour biopsy (unless bone-only disease).
8. Documented human epidermal growth factor receptor 2 negative (HER2-) tumor on most recent tumor biopsy.
9. Where regionally permitted, all patients must agree to provide if available a formalin-fixed paraffin embedded (FFPE) tissue biopsy sample taken at the time of presentation with recurrent or metastatic disease.
10. At least one lesion (measurable and/or non measurable) that can be accurately assessed at baseline with computerised tomography (CT) or magnetic resonance imaging (MRI) which is suitable for accurate repeated measurements.
11. Meet the following study part specific criteria related to previous therapy for breast cancer:
For Part A: Postmenopausal patient suitable for fulvestrant. Patient is allowed to have a maximum of 3 prior lines of chemotherapy. Previous treatment with CDK4/6 inhibitors is allowed
For Part B: Postmenopausal patient with locally advanced or metastatic ER+ve breast cancer and refractory to AIs defined as:
* Disease recurrence while on, or within 12 months of end of adjuvant treatment with letrozole, anastrozole, or exemestane, or
* Disease progression while on, or within one month of end of letrozole, anastrozole or exemestane treatment for locally advanced or metastatic breast cancer
* Letrozole or anastrozole do not have to be the last treatment prior to randomization.
* Patients who received one prior chemotherapy line for advanced/metastatic breast cancer are allowed.
Previous treatment with fulvestrant (or letrozole) is allowed. Other prior anticancer therapy (e.g. tamoxifen) are also allowed.
For inclusion in the optional research component:
1. Genetic research: Provision of signed and dated written consent for genetic research sampling and analyses. If a patient declines to participate in genetic component of the study, there will be no penalty or loss of benefit to the patient. The patient will not be excluded from other aspects of the study described in this Clinical Study Protocol, so long as they consent to the main study.
Exclusion:
1. Prior chemotherapy, biological therapy, radiation therapy, or immunotherapy, androgens, thalidomide, other anticancer agents, investigational drug or corticosteroids within 14 days. Patients who received prior radiotherapy to \>= 25% of bone marrow are not eligible independent of when it was received. Patients is not eligible if there are unresolved toxicities from prior therapy \> CTCAE grade 1 at the start of study treatment with the exception of alopecia.
2. Exposure to potent or moderate inhibitors or inducers of CYP3A4/5, Pgp (MDR1) or BCRP within stated washout periods.
3. Exposure to sensitive or narrow therapeutic range substrates of drug transporters OATP1B1, OATP1B3, MATE1 and MATE2K within wash-out period (5 x elimination half-life).
4 Exposure to proton pump inhibitors within wash-out period (5 x elimination half-life).
5\. Previous AZD2014, AZD8055 or other dual mTORC1/2 inhibitor
* In Part B only: Prior treatment with CDK4/6, or everolimus or any PI3K-mTOR pathway
6\. Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease. Patients with a history of CNS metastases or cord compression are eligible if definitively treated and clinically stable and off anticonvulsants and steroids for at least 4 weeks. Patients are not eligible if there is spinal cord compression and/or brain metastases, unless asymptomatic or treated and stable and off steroids for at least 4 weeks.
7\. Evidence of severe or uncontrolled systemic diseases such as:
• Severe hepatic impairment
• Interstitial lung disease (bilateral, diffuse, parenchymal lung disease)
* Current unstable or uncompensated respiratory or cardiac conditions
* Uncontrolled hypertension
* Active bleeding diatheses
* Any active infection
8\. Other malignancy within 3 years, except adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix
9\. Experienced any of the following currently or in the last 12 months:
* Coronary/peripheral artery bypass graft
* Angioplasty
* Vascular stent
* Myocardial infarction
* Angina pectoris
* Congestive heart failure NYHA Grade ≥ 2
* Ventricular arrhythmias requiring continuous therapy
* Supraventricular arrhythmias including atrial fibrillation of any grade
* Symptomatic pulmonary embolism
* Haemorrhagic or thrombotic stroke
10\. Abnormal ECHO or MUGA at baseline (LVEF \<50%).
11\. Mean resting QTc \>470 msec, family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation or Torsade de Pointes within 12 months.
12\. Clinically important abnormalities in rhythm, conduction or morphology of resting ECG.
13\. Hepatitis B (HBV), Hepatitis C (HCV) or Human Immunodeficiency virus (HIV).
14\. Concomitant medications known to predispose to Torsade de Pointes, or factors that increase the risk of QT prolongation or risk of arrhythmic events such as:
* Heart failure
* Hypokalaemia
* Congenital long QT syndrome
* Family history of long QT syndrome
* Family history of unexplained sudden death under 40 years-of-age
15\. Inadequate bone marrow reserve or organ function as demonstrated by:
* ANC \<1.5 x 10\^9/L.
* In Part A only - Cohorts of patients with specific baseline ANC range to be enrolled defined as follows: I) Low ANC patients: between 1.5 x 10\^9/L and 3.0 x 10\^9/L; ii) High ANC patients \> 3.0 x 10\^9/L.
* Platelets \<100 x 10\^9/L
* Haemoglobin \<90 g/L
* ALT \>2.5 x ULN or \> 5 x ULN in the presence of liver mets.
* AST \>2.5 x ULN or \> 5 x ULN in the presence of liver mets.
* Total bilirubin \>1.5 x ULN. Total bilirubin \>3 x ULN in patients with documented Gilbert's Syndrome.
* Serum creatinine \>1.5 x ULN concurrent with creatinine clearance ≤50 mL/min.
16\. Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi Syndrome or Renal tubular acidosis.
17\. Refractory nausea/vomiting, chronic GI diseases, inability to swallow the product or previous significant bowel resection.
18\. Hypersensitivity to excipients of AZD2014, Palbociclib or Fulvestrant or drugs with a similar structure.
19\. Diabetes Type I or uncontrolled Type II, as defined in WHO 2006 (fasting serum glucose of \> 7.0 mmol/L \[126 mg/dL\]).
20\. Patient with advanced/metastatic, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term including patients with massive uncontrolled effusions (pleural, pericardial, peritoneal), pulmonary lymphangitis, and over 50% of liver involvement in metastases.
21\. Prior hematopoietic stem cell or bone marrow transplant.
22\. Regular coumadin therapy. Low-molecular-weight heparin therapy or oral Factor Xa antagonists are allowed.
23\. Known abnormalities in coagulation, e.g. bleeding diathesis.
24\. Hematopoietic growth factors (such as erythropoietin, granulocyte colony stimulating factor \[G-CSF\], granulocyte macrophage colony stimulating factor \[GM-CSF\]) within 2 weeks prior. Primary prophylactic use of G-CSF is not permitted.
25\. Other severe acute or chronic psychiatric condition that may increase the risks associated with study participation.
2. Signed and dated written informed consent for tumour biopsies. If the tumour is found not to be safely accessible the biopsy will not be taken. Accessible lesions are defined as those which are biopsiable and amenable to repeat biopsy, unless clinically contraindicated. In this case the patient will remain in the study and there will be no penalty or loss of benefit to the patient and they will not be excluded from other aspects of the study.
3. Postmenopausal women aged ≥ 18 years
4. Negative pregnancy test prior to dosing and willing to use a highly effective method of contraception for the duration of the study and for 90 days after the last dose of IP if they are under 50 unless they have medically confirmed irreversible premature ovarian failure, bilateral oophorectomy, bilateral salpinectomy, or complete or partial hysterectomy.
Highly effective methods of contraception are:
• Use of oral, injected or implanted hormonal methods of contraception which inhibit ovulation, either estrogen and progestogen containing intravaginal, transdermal) or only progesterone containing (oral, injectable, implantable)
• Placement of an intrauterine device (IUD or intrauterine system (IUS)
• True abstinence
* Bilateral tubal ligation
* Vasectomised partner
5. World Health Organisation/Eastern Cooperative Oncology Group (ECOG) performance status of patient is 0-1 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks.
6. Histologically or cytologically proven diagnosis of breast cancer with evidence of locally advanced or metastatic disease, not amenable to resection or radiation therapy with curative intent.
7. Documentation of estrogen receptor positive (ER+) breast cancer based on most recent tumour biopsy (unless bone-only disease).
8. Documented human epidermal growth factor receptor 2 negative (HER2-) tumor on most recent tumor biopsy.
9. Where regionally permitted, all patients must agree to provide if available a formalin-fixed paraffin embedded (FFPE) tissue biopsy sample taken at the time of presentation with recurrent or metastatic disease.
10. At least one lesion (measurable and/or non measurable) that can be accurately assessed at baseline with computerised tomography (CT) or magnetic resonance imaging (MRI) which is suitable for accurate repeated measurements.
11. Meet the following study part specific criteria related to previous therapy for breast cancer:
For Part A: Postmenopausal patient suitable for fulvestrant. Patient is allowed to have a maximum of 3 prior lines of chemotherapy. Previous treatment with CDK4/6 inhibitors is allowed
For Part B: Postmenopausal patient with locally advanced or metastatic ER+ve breast cancer and refractory to AIs defined as:
* Disease recurrence while on, or within 12 months of end of adjuvant treatment with letrozole, anastrozole, or exemestane, or
* Disease progression while on, or within one month of end of letrozole, anastrozole or exemestane treatment for locally advanced or metastatic breast cancer
* Letrozole or anastrozole do not have to be the last treatment prior to randomization.
* Patients who received one prior chemotherapy line for advanced/metastatic breast cancer are allowed.
Previous treatment with fulvestrant (or letrozole) is allowed. Other prior anticancer therapy (e.g. tamoxifen) are also allowed.
For inclusion in the optional research component:
1. Genetic research: Provision of signed and dated written consent for genetic research sampling and analyses. If a patient declines to participate in genetic component of the study, there will be no penalty or loss of benefit to the patient. The patient will not be excluded from other aspects of the study described in this Clinical Study Protocol, so long as they consent to the main study.
Exclusion:
1. Prior chemotherapy, biological therapy, radiation therapy, or immunotherapy, androgens, thalidomide, other anticancer agents, investigational drug or corticosteroids within 14 days. Patients who received prior radiotherapy to \>= 25% of bone marrow are not eligible independent of when it was received. Patients is not eligible if there are unresolved toxicities from prior therapy \> CTCAE grade 1 at the start of study treatment with the exception of alopecia.
2. Exposure to potent or moderate inhibitors or inducers of CYP3A4/5, Pgp (MDR1) or BCRP within stated washout periods.
3. Exposure to sensitive or narrow therapeutic range substrates of drug transporters OATP1B1, OATP1B3, MATE1 and MATE2K within wash-out period (5 x elimination half-life).
4 Exposure to proton pump inhibitors within wash-out period (5 x elimination half-life).
5\. Previous AZD2014, AZD8055 or other dual mTORC1/2 inhibitor
* In Part B only: Prior treatment with CDK4/6, or everolimus or any PI3K-mTOR pathway
6\. Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease. Patients with a history of CNS metastases or cord compression are eligible if definitively treated and clinically stable and off anticonvulsants and steroids for at least 4 weeks. Patients are not eligible if there is spinal cord compression and/or brain metastases, unless asymptomatic or treated and stable and off steroids for at least 4 weeks.
7\. Evidence of severe or uncontrolled systemic diseases such as:
• Severe hepatic impairment
• Interstitial lung disease (bilateral, diffuse, parenchymal lung disease)
* Current unstable or uncompensated respiratory or cardiac conditions
* Uncontrolled hypertension
* Active bleeding diatheses
* Any active infection
8\. Other malignancy within 3 years, except adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix
9\. Experienced any of the following currently or in the last 12 months:
* Coronary/peripheral artery bypass graft
* Angioplasty
* Vascular stent
* Myocardial infarction
* Angina pectoris
* Congestive heart failure NYHA Grade ≥ 2
* Ventricular arrhythmias requiring continuous therapy
* Supraventricular arrhythmias including atrial fibrillation of any grade
* Symptomatic pulmonary embolism
* Haemorrhagic or thrombotic stroke
10\. Abnormal ECHO or MUGA at baseline (LVEF \<50%).
11\. Mean resting QTc \>470 msec, family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation or Torsade de Pointes within 12 months.
12\. Clinically important abnormalities in rhythm, conduction or morphology of resting ECG.
13\. Hepatitis B (HBV), Hepatitis C (HCV) or Human Immunodeficiency virus (HIV).
14\. Concomitant medications known to predispose to Torsade de Pointes, or factors that increase the risk of QT prolongation or risk of arrhythmic events such as:
* Heart failure
* Hypokalaemia
* Congenital long QT syndrome
* Family history of long QT syndrome
* Family history of unexplained sudden death under 40 years-of-age
15\. Inadequate bone marrow reserve or organ function as demonstrated by:
* ANC \<1.5 x 10\^9/L.
* In Part A only - Cohorts of patients with specific baseline ANC range to be enrolled defined as follows: I) Low ANC patients: between 1.5 x 10\^9/L and 3.0 x 10\^9/L; ii) High ANC patients \> 3.0 x 10\^9/L.
* Platelets \<100 x 10\^9/L
* Haemoglobin \<90 g/L
* ALT \>2.5 x ULN or \> 5 x ULN in the presence of liver mets.
* AST \>2.5 x ULN or \> 5 x ULN in the presence of liver mets.
* Total bilirubin \>1.5 x ULN. Total bilirubin \>3 x ULN in patients with documented Gilbert's Syndrome.
* Serum creatinine \>1.5 x ULN concurrent with creatinine clearance ≤50 mL/min.
16\. Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi Syndrome or Renal tubular acidosis.
17\. Refractory nausea/vomiting, chronic GI diseases, inability to swallow the product or previous significant bowel resection.
18\. Hypersensitivity to excipients of AZD2014, Palbociclib or Fulvestrant or drugs with a similar structure.
19\. Diabetes Type I or uncontrolled Type II, as defined in WHO 2006 (fasting serum glucose of \> 7.0 mmol/L \[126 mg/dL\]).
20\. Patient with advanced/metastatic, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term including patients with massive uncontrolled effusions (pleural, pericardial, peritoneal), pulmonary lymphangitis, and over 50% of liver involvement in metastases.
21\. Prior hematopoietic stem cell or bone marrow transplant.
22\. Regular coumadin therapy. Low-molecular-weight heparin therapy or oral Factor Xa antagonists are allowed.
23\. Known abnormalities in coagulation, e.g. bleeding diathesis.
24\. Hematopoietic growth factors (such as erythropoietin, granulocyte colony stimulating factor \[G-CSF\], granulocyte macrophage colony stimulating factor \[GM-CSF\]) within 2 weeks prior. Primary prophylactic use of G-CSF is not permitted.
25\. Other severe acute or chronic psychiatric condition that may increase the risks associated with study participation.
Minimum Eligible Age
18 Years
Maximum Eligible Age
130 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anja Wiliams
Role: PRINCIPAL_INVESTIGATOR
Sarah Cannon Research Institute UK
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Encinitas, California, United States
Site Status
Research Site
Sarasota, Florida, United States
Site Status
Research Site
Detroit, Michigan, United States
Site Status
Research Site
Nashville, Tennessee, United States
Site Status
Research Site
Milwaukee, Wisconsin, United States
Site Status
Research Site
Liverpool, , United Kingdom
Site Status
Research Site
London, , United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
United Kingdom
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
264477
Identifier Type: OTHER
Identifier Source: secondary_id
2015-003320-30
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
D2270C00020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer
NCT02491983
COMPLETED
PHASE2
Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy
NCT04524728
COMPLETED
Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate
NCT02142868
NO_LONGER_AVAILABLE
AZD9496 First Time in Patients Ascending Dose Study
NCT02248090
COMPLETED
PHASE1
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
NCT06062498
RECRUITING
PHASE2
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
NCT04740918
TERMINATED
PHASE3
Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
NCT03238196
COMPLETED
PHASE1
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
NCT03079011
COMPLETED
PHASE3
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
NCT02894398
COMPLETED
PHASE2
A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread
NCT02322814
TERMINATED
PHASE2
Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
NCT02536742
COMPLETED
PHASE2
TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.
NCT04498481
COMPLETED
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
NCT04288089
ACTIVE_NOT_RECRUITING
PHASE1
Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib
NCT02913430
COMPLETED
EARLY_PHASE1
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
NCT07002177
RECRUITING
PHASE1/PHASE2
A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer
NCT04060862
TERMINATED
PHASE1
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
NCT03566485
TERMINATED
PHASE1/PHASE2
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
NCT06756932
RECRUITING
PHASE1
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
NCT05806671
NOT_YET_RECRUITING
PHASE2
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
NCT03125902
COMPLETED
PHASE3
A Study of LY3023414 in Participants With Advanced Cancer
NCT01655225
COMPLETED
PHASE1
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
NCT03371017
COMPLETED
PHASE3
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
NCT02057133
ACTIVE_NOT_RECRUITING
PHASE1